GenVec to Release Second Quarter 2011 Financial Results and Conduct a Conference Call on August 9, 2011

GAITHERSBURG, Md., Aug. 2, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) will report financial results for the second quarter of 2011 on Tuesday, August 9, 2011, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call at 10:00 a.m. EDT to discuss the company's second quarter financial results and business outlook.

To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 84527868. An audio replay of the conference call will be available starting at 1:00 p.m. EDT on August 9, 2011 through August 16, 2011. To listen to the audio replay, dial 855-859-2056 or 404-537-3406 and use Conference Replay ID: 84527868.

To access the webcast or the replay, go to www.genvec.com, click on "Investors and Media," and click on "Events and Presentations."

About GenVec

GenVec, Inc. is a biopharmaceutical company using superior, proprietary technology to create differentiated vaccines and therapeutics that are developed and commercialized through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the US Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), HSV-2, dengue fever, influenza, HIV, malaria, and foot-and-mouth disease. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Retail Investor and Media Contact:

Institutional Investor Contact:

GenVec, Inc.

S.A. Noonan Communications

Douglas J. Swirsky

Susan A. Noonan

(240) 632-5510

(212) 966-3650

[email protected]

[email protected]



SOURCE GenVec, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.